Prospects for development of new antimycobacterial drugs, with special reference to a new benzoxazinorifamycin, KRM-1648

Archivum Immunologiae et Therapiae Experimentalis

Volumn 48, Issue 3, 2000, Pages 183-188

  Tomioka, Haruaki ^a  

^a SHIMANE UNIVERSITY   (Japan)

Author keywords

Fluoroquinolones; Mycobacterial infection; Mycobacterium avium complex; Mycobacterium tuberculosis; New macrolides; Rifamycin

Indexed keywords

1 CYCLOPROPYL 7 (3 ETHYL 1 PIPERAZINYL) 6 FLUORO 1,4 DIHYDRO 8 METHOXY 4 OXO 3 QUINOLINECARBOXYLIC ACID; 1 CYCLOPROPYL 7 FLUORO 9 METHYL 8 (OCTAHYDROPYRROLO[3,4 B]PYRIDIN 6 YL) 4 OXO 3 QUINOLIZINECARBOXYLIC ACID; 3 [(1 DIETHYLAMINOETHYLIDENE)AZINOMETHYL]RIFAMYCIN SV; 3 [(4 ISOBUTYL 1 PIPERAZINYL)IMINOMETHYL]RIFAMYCIN SV; 3 [4 (2,4,6 TRIMETHYLBENZYL) 1 PIPERAZINYL]RIFAMYCIN SV; 3 PIPERIDINOMETHYLAZINOMETHYLRIFAMYCIN SV; AZITHROMYCIN; BALOFLOXACIN; CGP 27557; CGP 29861; CIPROFLOXACIN; CLARITHROMYCIN; DL 437; ENOXACIN; FCE 22807; FLEROXACIN; GATIFLOXACIN; GREPAFLOXACIN; LEVOFLOXACIN; LOMEFLOXACIN; MACROLIDE; MDL 437; MEFLOQUINE; MOXIFLOXACIN; NADIFLOXACIN; OFLOXACIN; PYRIDONE DERIVATIVE; QUINOLINE DERIVED ANTIINFECTIVE AGENT; RIFABUTIN; RIFALAZIL; RIFAMYCIN DERIVATIVE; RIFAPENTINE; ROXITHROMYCIN; SITAFLOXACIN; SPARFLOXACIN; TEMAFLOXACIN; UNCLASSIFIED DRUG; UNINDEXED DRUG;

ANTIBACTERIAL ACTIVITY; CLINICAL TRIAL; DRUG BLOOD LEVEL; DRUG DISTRIBUTION; DRUG EFFICACY; DRUG ELIMINATION; DRUG POTENCY; HUMAN; MINIMUM INHIBITORY CONCENTRATION; MULTIDRUG RESISTANCE; MYCOBACTERIOSIS; MYCOBACTERIUM AVIUM; MYCOBACTERIUM TUBERCULOSIS; NONHUMAN; REVIEW; TUBERCULOSIS;

ANIMALS; ANTI-BACTERIAL AGENTS; ANTI-INFECTIVE AGENTS; ANTIBIOTICS, ANTITUBERCULAR; DRUG DESIGN; FLUOROQUINOLONES; HUMANS; MACROLIDES; MYCOBACTERIUM; MYCOBACTERIUM AVIUM COMPLEX; MYCOBACTERIUM INFECTIONS; MYCOBACTERIUM TUBERCULOSIS; RIFAMYCINS; TUBERCULOSIS;

EID: 0033864314     PISSN: 0004069X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (12)

1. ALANGADEN G. J. and LERNER S. A. (1997): The clinical use of fluoroquinolones for the treatment of mycobacterial diseases. Clin. Inefct. Dis., 25, 1213-1221.
2. AMSDEN G. W., PELOQUIN C. A. and BERNING S. E. (1997): The role of advanced generation macrolides in the prophylaxis and treatment of Mycobacterium avium complex (MAC) infections. Drugs, 54, 69-80.
3. COHN D. L. and ISEMAN M. D. (1993): Treatment and prevention of multidrug-resistant tuberculosis. Res. Microbiol., 144, 150-153.
4. DAUZENBERG B. (1994): Clinical trials in Mycobacterium avium therapy: lessons to take home. Res. Microbiol., 145, 197-206.
5. GRASSI C. (1997): New drugs for tuberculosis. Exp. Opin. Invest. Drugs, 6, 1211-1226.
6. HEIFETS L. (1996): Clarithromycin against Mycobacterium avium complex infection. Tuberc. Lung Dis., 77, 19-26.
7. HIRATA T., SAITO H., TOMIOKA H. et al. (1995): In vitro and in vivo activities of the benzoxazinorifamycin KRM-1648 against Mycobacterium tuberculosis. Antimicrob. Agents Chemother., 39, 2295-2303.
8. KUNIN C. M. (1996): Antimicrobial activity of rifabutin. Clin. Infect. Dis., 22 (suppl. 1), S3-14.
9. TOMIOKA H., SAITO H., SATO K. et al. (1992): Chemotherapeutic efficacy of a newly synthesized benzoxazinorifamycin, KRM-1648, against Mycobacterium avium complex infection induced in mice. Antimicrob. Agents Chemother., 36, 387-393.
10. TOMIOKA H., SATO K., SAITO H. et al. (1997): In vitro and in vivo antimycobacterial activities of KRM-1648, a new benzoxazinorifamycin. In PANDALI S. G.: Recent research developments in antimicrobial agents and chemotherapy. Research Signpost, Trivandrum, 37-68.
11. YAJKO D. M., SANDERS C. A., MADEJ J. J. et al. (1996): In vitro activities of rifabutin, azithromycin, ciprofloxacin, clarithromycin, clofazimine, ethambutol, and amikacin in combinations of two, three, and four drugs against Mycobacterium avium. Antimicrob. Agents Chemother., 40, 743-749.
12. YEW W. W. and CHAU C. H. (1996): New antimycobacterial agents. Monaldi Arch. Chest Dis., 51, 394-404.